 | • レポートコード：MRC2Q12-16815 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、成人用希少疾病用医薬品のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 成人用希少疾病用医薬品のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 成人用希少疾病用医薬品の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 成人用希少疾病用医薬品のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの成人用希少疾病用医薬品の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の成人用希少疾病用医薬品の売上および2028年までの予測に焦点を当てています。 成人用希少疾病用医薬品のグローバル主要企業には、Abbvie Inc.、Orpharma、Amgen Inc.、Recordati SpA、Novartis、Celgene、Amryt Pharma Plc.、Johnson & Johnson、GSK Plc.、Bristol-Myers Squibb Company、Roche Holding、Sanofi、Takeda、Pfizer、Vertex Pharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 成人用希少疾病用医薬品市場は、タイプとアプリケーションによって区分されます。世界の成人用希少疾病用医薬品市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 抗がん剤、胃腸薬、神経薬、循環器薬、その他 【アプリケーション別セグメント】 病院薬局、小売店、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 成人用希少疾病用医薬品製品概要 - タイプ別市場（抗がん剤、胃腸薬、神経薬、循環器薬、その他） - アプリケーション別市場（病院薬局、小売店、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の成人用希少疾病用医薬品販売量予測2017-2028 - 世界の成人用希少疾病用医薬品売上予測2017-2028 - 成人用希少疾病用医薬品の地域別販売量 - 成人用希少疾病用医薬品の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別成人用希少疾病用医薬品販売量 - 主要メーカー別成人用希少疾病用医薬品売上 - 主要メーカー別成人用希少疾病用医薬品価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（抗がん剤、胃腸薬、神経薬、循環器薬、その他） - 成人用希少疾病用医薬品のタイプ別販売量 - 成人用希少疾病用医薬品のタイプ別売上 - 成人用希少疾病用医薬品のタイプ別価格 ・アプリケーション別市場規模（病院薬局、小売店、その他） - 成人用希少疾病用医薬品のアプリケーション別販売量 - 成人用希少疾病用医薬品のアプリケーション別売上 - 成人用希少疾病用医薬品のアプリケーション別価格 ・北米市場 - 北米の成人用希少疾病用医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の成人用希少疾病用医薬品市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの成人用希少疾病用医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の成人用希少疾病用医薬品市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の成人用希少疾病用医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の成人用希少疾病用医薬品市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の成人用希少疾病用医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の成人用希少疾病用医薬品市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの成人用希少疾病用医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の成人用希少疾病用医薬品市場規模（トルコ、サウジアラビア） ・企業情報 Abbvie Inc.、Orpharma、Amgen Inc.、Recordati SpA、Novartis、Celgene、Amryt Pharma Plc.、Johnson & Johnson、GSK Plc.、Bristol-Myers Squibb Company、Roche Holding、Sanofi、Takeda、Pfizer、Vertex Pharmaceuticals ・産業チェーン及び販売チャネル分析 - 成人用希少疾病用医薬品の産業チェーン分析 - 成人用希少疾病用医薬品の原材料 - 成人用希少疾病用医薬品の生産プロセス - 成人用希少疾病用医薬品の販売及びマーケティング - 成人用希少疾病用医薬品の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 成人用希少疾病用医薬品の産業動向 - 成人用希少疾病用医薬品のマーケットドライバー - 成人用希少疾病用医薬品の課題 - 成人用希少疾病用医薬品の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Orphan Drugs for Adults estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Orphan Drugs for Adults is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Orphan Drugs for Adults is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Orphan Drugs for Adults is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Orphan Drugs for Adults include Abbvie Inc., Orpharma, Amgen Inc., Recordati SpA, Novartis, Celgene, Amryt Pharma Plc., Johnson & Johnson and GSK Plc., etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Orphan Drugs for Adults companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Orphan Drugs for Adults market. Further, it explains the major drivers and regional dynamics of the global Orphan Drugs for Adults market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Abbvie Inc.
Orpharma
Amgen Inc.
Recordati SpA
Novartis
Celgene
Amryt Pharma Plc.
Johnson & Johnson
GSK Plc.
Bristol-Myers Squibb Company
Roche Holding
Sanofi
Takeda
Pfizer
Vertex Pharmaceuticals
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Orphan Drugs for Adults Segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Orphan Drugs for Adults Segment by Application
Hospital Pharmacies
Retail pharmacies
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Orphan Drugs for Adults market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Orphan Drugs for Adults market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Orphan Drugs for Adults, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Orphan Drugs for Adults, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Orphan Drugs for Adults revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Orphan Drugs for Adults market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Orphan Drugs for Adults revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Abbvie Inc., Orpharma, Amgen Inc., Recordati SpA, Novartis, Celgene, Amryt Pharma Plc., Johnson & Johnson and GSK Plc., etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Orphan Drugs for Adults in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Orphan Drugs for Adults companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Orphan Drugs for Adults revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Orphan Drugs for Adults Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oncology Drugs
1.2.3 Gastrointestinal Drugs
1.2.4 Neurology Drugs
1.2.5 Cardio-vascular Drugs
1.2.6 Others
1.3 Market by Application
1.3.1 Global Orphan Drugs for Adults Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail pharmacies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Orphan Drugs for Adults Market Perspective (2017-2028)
2.2 Orphan Drugs for Adults Growth Trends by Region
2.2.1 Orphan Drugs for Adults Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Orphan Drugs for Adults Historic Market Size by Region (2017-2022)
2.2.3 Orphan Drugs for Adults Forecasted Market Size by Region (2023-2028)
2.3 Orphan Drugs for Adults Market Dynamics
2.3.1 Orphan Drugs for Adults Industry Trends
2.3.2 Orphan Drugs for Adults Market Drivers
2.3.3 Orphan Drugs for Adults Market Challenges
2.3.4 Orphan Drugs for Adults Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Orphan Drugs for Adults Players by Revenue
3.1.1 Global Top Orphan Drugs for Adults Players by Revenue (2017-2022)
3.1.2 Global Orphan Drugs for Adults Revenue Market Share by Players (2017-2022)
3.2 Global Orphan Drugs for Adults Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Orphan Drugs for Adults Revenue
3.4 Global Orphan Drugs for Adults Market Concentration Ratio
3.4.1 Global Orphan Drugs for Adults Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs for Adults Revenue in 2021
3.5 Orphan Drugs for Adults Key Players Head office and Area Served
3.6 Key Players Orphan Drugs for Adults Product Solution and Service
3.7 Date of Enter into Orphan Drugs for Adults Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Orphan Drugs for Adults Breakdown Data by Type
4.1 Global Orphan Drugs for Adults Historic Market Size by Type (2017-2022)
4.2 Global Orphan Drugs for Adults Forecasted Market Size by Type (2023-2028)
5 Orphan Drugs for Adults Breakdown Data by Application
5.1 Global Orphan Drugs for Adults Historic Market Size by Application (2017-2022)
5.2 Global Orphan Drugs for Adults Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Orphan Drugs for Adults Market Size (2017-2028)
6.2 North America Orphan Drugs for Adults Market Size by Type
6.2.1 North America Orphan Drugs for Adults Market Size by Type (2017-2022)
6.2.2 North America Orphan Drugs for Adults Market Size by Type (2023-2028)
6.2.3 North America Orphan Drugs for Adults Market Share by Type (2017-2028)
6.3 North America Orphan Drugs for Adults Market Size by Application
6.3.1 North America Orphan Drugs for Adults Market Size by Application (2017-2022)
6.3.2 North America Orphan Drugs for Adults Market Size by Application (2023-2028)
6.3.3 North America Orphan Drugs for Adults Market Share by Application (2017-2028)
6.4 North America Orphan Drugs for Adults Market Size by Country
6.4.1 North America Orphan Drugs for Adults Market Size by Country (2017-2022)
6.4.2 North America Orphan Drugs for Adults Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Orphan Drugs for Adults Market Size (2017-2028)
7.2 Europe Orphan Drugs for Adults Market Size by Type
7.2.1 Europe Orphan Drugs for Adults Market Size by Type (2017-2022)
7.2.2 Europe Orphan Drugs for Adults Market Size by Type (2023-2028)
7.2.3 Europe Orphan Drugs for Adults Market Share by Type (2017-2028)
7.3 Europe Orphan Drugs for Adults Market Size by Application
7.3.1 Europe Orphan Drugs for Adults Market Size by Application (2017-2022)
7.3.2 Europe Orphan Drugs for Adults Market Size by Application (2023-2028)
7.3.3 Europe Orphan Drugs for Adults Market Share by Application (2017-2028)
7.4 Europe Orphan Drugs for Adults Market Size by Country
7.4.1 Europe Orphan Drugs for Adults Market Size by Country (2017-2022)
7.4.2 Europe Orphan Drugs for Adults Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Orphan Drugs for Adults Market Size (2017-2028)
8.2 Asia-Pacific Orphan Drugs for Adults Market Size by Type
8.2.1 Asia-Pacific Orphan Drugs for Adults Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Orphan Drugs for Adults Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Orphan Drugs for Adults Market Share by Type (2017-2028)
8.3 Asia-Pacific Orphan Drugs for Adults Market Size by Application
8.3.1 Asia-Pacific Orphan Drugs for Adults Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Orphan Drugs for Adults Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Orphan Drugs for Adults Market Share by Application (2017-2028)
8.4 Asia-Pacific Orphan Drugs for Adults Market Size by Region
8.4.1 Asia-Pacific Orphan Drugs for Adults Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Orphan Drugs for Adults Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Orphan Drugs for Adults Market Size (2017-2028)
9.2 Latin America Orphan Drugs for Adults Market Size by Type
9.2.1 Latin America Orphan Drugs for Adults Market Size by Type (2017-2022)
9.2.2 Latin America Orphan Drugs for Adults Market Size by Type (2023-2028)
9.2.3 Latin America Orphan Drugs for Adults Market Share by Type (2017-2028)
9.3 Latin America Orphan Drugs for Adults Market Size by Application
9.3.1 Latin America Orphan Drugs for Adults Market Size by Application (2017-2022)
9.3.2 Latin America Orphan Drugs for Adults Market Size by Application (2023-2028)
9.3.3 Latin America Orphan Drugs for Adults Market Share by Application (2017-2028)
9.4 Latin America Orphan Drugs for Adults Market Size by Country
9.4.1 Latin America Orphan Drugs for Adults Market Size by Country (2017-2022)
9.4.2 Latin America Orphan Drugs for Adults Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Orphan Drugs for Adults Market Size (2017-2028)
10.2 Middle East & Africa Orphan Drugs for Adults Market Size by Type
10.2.1 Middle East & Africa Orphan Drugs for Adults Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Orphan Drugs for Adults Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Orphan Drugs for Adults Market Share by Type (2017-2028)
10.3 Middle East & Africa Orphan Drugs for Adults Market Size by Application
10.3.1 Middle East & Africa Orphan Drugs for Adults Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Orphan Drugs for Adults Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Orphan Drugs for Adults Market Share by Application (2017-2028)
10.4 Middle East & Africa Orphan Drugs for Adults Market Size by Country
10.4.1 Middle East & Africa Orphan Drugs for Adults Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Orphan Drugs for Adults Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbvie Inc.
11.1.1 Abbvie Inc. Company Details
11.1.2 Abbvie Inc. Business Overview
11.1.3 Abbvie Inc. Orphan Drugs for Adults Introduction
11.1.4 Abbvie Inc. Revenue in Orphan Drugs for Adults Business (2017-2022)
11.1.5 Abbvie Inc. Recent Developments
11.2 Orpharma
11.2.1 Orpharma Company Details
11.2.2 Orpharma Business Overview
11.2.3 Orpharma Orphan Drugs for Adults Introduction
11.2.4 Orpharma Revenue in Orphan Drugs for Adults Business (2017-2022)
11.2.5 Orpharma Recent Developments
11.3 Amgen Inc.
11.3.1 Amgen Inc. Company Details
11.3.2 Amgen Inc. Business Overview
11.3.3 Amgen Inc. Orphan Drugs for Adults Introduction
11.3.4 Amgen Inc. Revenue in Orphan Drugs for Adults Business (2017-2022)
11.3.5 Amgen Inc. Recent Developments
11.4 Recordati SpA
11.4.1 Recordati SpA Company Details
11.4.2 Recordati SpA Business Overview
11.4.3 Recordati SpA Orphan Drugs for Adults Introduction
11.4.4 Recordati SpA Revenue in Orphan Drugs for Adults Business (2017-2022)
11.4.5 Recordati SpA Recent Developments
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Orphan Drugs for Adults Introduction
11.5.4 Novartis Revenue in Orphan Drugs for Adults Business (2017-2022)
11.5.5 Novartis Recent Developments
11.6 Celgene
11.6.1 Celgene Company Details
11.6.2 Celgene Business Overview
11.6.3 Celgene Orphan Drugs for Adults Introduction
11.6.4 Celgene Revenue in Orphan Drugs for Adults Business (2017-2022)
11.6.5 Celgene Recent Developments
11.7 Amryt Pharma Plc.
11.7.1 Amryt Pharma Plc. Company Details
11.7.2 Amryt Pharma Plc. Business Overview
11.7.3 Amryt Pharma Plc. Orphan Drugs for Adults Introduction
11.7.4 Amryt Pharma Plc. Revenue in Orphan Drugs for Adults Business (2017-2022)
11.7.5 Amryt Pharma Plc. Recent Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Orphan Drugs for Adults Introduction
11.8.4 Johnson & Johnson Revenue in Orphan Drugs for Adults Business (2017-2022)
11.8.5 Johnson & Johnson Recent Developments
11.9 GSK Plc.
11.9.1 GSK Plc. Company Details
11.9.2 GSK Plc. Business Overview
11.9.3 GSK Plc. Orphan Drugs for Adults Introduction
11.9.4 GSK Plc. Revenue in Orphan Drugs for Adults Business (2017-2022)
11.9.5 GSK Plc. Recent Developments
11.10 Bristol-Myers Squibb Company
11.10.1 Bristol-Myers Squibb Company Company Details
11.10.2 Bristol-Myers Squibb Company Business Overview
11.10.3 Bristol-Myers Squibb Company Orphan Drugs for Adults Introduction
11.10.4 Bristol-Myers Squibb Company Revenue in Orphan Drugs for Adults Business (2017-2022)
11.10.5 Bristol-Myers Squibb Company Recent Developments
11.11 Roche Holding
11.11.1 Roche Holding Company Details
11.11.2 Roche Holding Business Overview
11.11.3 Roche Holding Orphan Drugs for Adults Introduction
11.11.4 Roche Holding Revenue in Orphan Drugs for Adults Business (2017-2022)
11.11.5 Roche Holding Recent Developments
11.12 Sanofi
11.12.1 Sanofi Company Details
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Orphan Drugs for Adults Introduction
11.12.4 Sanofi Revenue in Orphan Drugs for Adults Business (2017-2022)
11.12.5 Sanofi Recent Developments
11.13 Takeda
11.13.1 Takeda Company Details
11.13.2 Takeda Business Overview
11.13.3 Takeda Orphan Drugs for Adults Introduction
11.13.4 Takeda Revenue in Orphan Drugs for Adults Business (2017-2022)
11.13.5 Takeda Recent Developments
11.14 Pfizer
11.14.1 Pfizer Company Details
11.14.2 Pfizer Business Overview
11.14.3 Pfizer Orphan Drugs for Adults Introduction
11.14.4 Pfizer Revenue in Orphan Drugs for Adults Business (2017-2022)
11.14.5 Pfizer Recent Developments
11.15 Vertex Pharmaceuticals
11.15.1 Vertex Pharmaceuticals Company Details
11.15.2 Vertex Pharmaceuticals Business Overview
11.15.3 Vertex Pharmaceuticals Orphan Drugs for Adults Introduction
11.15.4 Vertex Pharmaceuticals Revenue in Orphan Drugs for Adults Business (2017-2022)
11.15.5 Vertex Pharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer